Latest Conference Articles

James Allison Predicts 'Cures' With Checkpoint Inhibitor Combinations

Since the approval of the first checkpoint inhibitor, ipilimumab, several combinations and monotherapies have gained rapid approval, with continued expansion on the horizon.

Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

Immune Checkpoint Inhibitors Hold Promise In Glioblastoma

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

Second-Line Optune Improves Survival in GBM

The addition of Optune to chemotherapy and/or bevacizumab improved survival in patients with recurrent glioblastoma multiforme.

Dr. Reardon on Updated Data From the Phase II ReACT Trial

David Reardon, MD, discusses updated survival findings from the phase II ReACT trial, which analyzed rindopepimut (CDX-110) plus bevacizumab for the treatment of relapsed glioblastoma.

Dr. Jason Luke on Utilizing the Tumor Microenvironment as a Biomarker for Immunotherapy Response

Jason Luke, MD, Assistant Professor of Medicine, the University of Chicago Medicine Comprehensive Cancer Center, discusses how inflammation in the tumor microenvironment can serve as a biomarker in melanoma.

Testing Checkpoint Inhibitors in Brain Cancer Requires Careful AE Management

As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.

Nivolumab Survival Benefit Sustained in Long-Term Melanoma Data

Long-term data continue to show sustained improvements in overall survival with nivolumab alone or in combination with ipilimumab as a frontline treatment for patients with advanced melanoma.

Novel Agents, T-VEC Combos Mark Next Phase of Oncolytic Immunotherapy Era in Melanoma

With the FDA approval of the first oncolytic immunotherapy-talimogene laherparepvec (T-VEC; Imlygic)-the stage has been set for increased research into these agents.

Dr. Michael Krauthammer on NF1 Mutations in Melanoma

Michael Krauthammer, MD, PhD, Associate Professor of Pathology, Yale School of Medicine, discusses the role of NF1 mutation in melanoma.

QoL Similar With Checkpoint Combo Versus Single-Agents in Melanoma

There were few differences in quality of life, global health, and symptom burden between patients with melanoma who were treated with nivolumab plus ipilimumab or either agent alone.

Researchers Seek to Improve Responses With Checkpoint Inhibitors

Predictive genetic signatures and novel combination strategies may be the key to improving the often dramatic responses seen with immune checkpoint inhibitors.

Dr. Sancy Leachman on Helping Patients Identify Melanoma Recurrences

Sancy Leachman, MD,PhD, Professor and Chair, Department of Dermatology Director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses a new tool that oncologists can use with patients to identify melanoma recurrences.

Sheri Holmen on Understanding Drivers of Melanoma Metastasis

Sheri Holmen, PhD, investigator, Associate Professor in the Department of Surgery, Adjunct Professor in the Department of Oncological Sciences, Huntsman Cancer Institute, the University of Utah School of Medicine, discusses understanding drivers for melanoma metastasis.

New Treatments for Novel Targets Next Step in Immuno-Oncology Revolution

There is a wide variety of novel targets and corresponding checkpoint and immune blocker/activator therapies that may soon show promise in cancer care.

Dr. Brose on Unique Elements of the Lenvatinib Trial

Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses the lenvatinib trial.

Dr. Lynch on Targeting EGFR Mutation Subtypes in Lung Cancer

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Dr. Ruben Mesa on Advancements in Polycythemia Vera

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses advancements in polycythemia vera (PV).

Dr. Waxman on Advancements in Acute Promyelocytic Leukemia

Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia.

Dr. Koo Discusses Focal Therapy for Prostate Cancer

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.

Dr. Kirsh Discusses the Future of Treating Prostate Cancer

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

Dr. Oxnard on Delaying Second-Line Treatment in EGFR-Mutant Lung Cancer

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses how to define resistance to EGFR-inhibitors in lung cancer.

PD-1 Agents Top Choice for Second-Line NSCLC

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.

Expert Examines Nuances of Switching Therapies in Progressive EGFR-Positive NSCLC

Patience is a virtue when it comes to deciding whether to switch therapies for individuals with metastatic non–small cell lung cancer who appear to be progressing on an EGFR-targeting regimen.

Upfront EGFR TKI Questions Remain in NSCLC

Multiple options currently exist for patients with EGFR-positive non–small cell lung cancer, with additional therapies on the horizon, making upfront treatment selection an increasingly difficult endeavor.

Dr. Levy on EGFR TKIs in Lung Cancer

Benjamin P. Levy, MD, attending physician, Department of Medicine, Mount Sinai Beth Israel and Mount Sinai St. Luke's Roosevelt, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

Dr. Buffington on Degarelix and Appropriate Patients

Philip J. Buffington, MD, chief medical officer at The Urology Group, discusses administering degarelix (Firmagon) and determining which patients to treat with the hormonal therapy.buffington-thumb.jpg

Nivolumab Demonstrates Broad Efficacy in NSCLC

The latest FDA approval for nivolumab in non–small cell lung cancer means that the drug potentially can be administered to any patient in the second-line setting, regardless of tumor histology or PD-L1 expression level.

Targeting Rare Mutations in NSCLC the Way of the Future

Treatment of patients with non–small cell lung cancer should be based on the identification of rare molecular targets such as BRAF, RET, ROS1, and MET versus clinical characteristics.